IMP3 and serous adenocarcinoma: In a subsequent study on 401 cases, the same authors found 78% of serous carcinomas, 57% of clear cell carcinomas and 15% of endometrioid carcinomas IMP3 positive by using a combined scoring system for intensity and percentage of expression [17].